M&A Deal Summary

Galecto Acquires Damora

On November 10, 2025, Galecto acquired life science company Damora for 285M USD

Acquisition Highlights
  • This is Galecto’s 2nd transaction in the Life Science sector.
  • This is Galecto’s largest (disclosed) transaction.
  • This is Galecto’s 2nd transaction in the United States.
  • This is Galecto’s 1st transaction in Massachusetts.

M&A Deal Summary

Date 2025-11-10
Target Damora
Sector Life Science
Buyer(s) Galecto
Deal Type Add-on Acquisition
Deal Value 285M USD

Target

Damora

Waltham, Massachusetts, United States
Damora is a biotechnology company focused on developing therapeutic antibodies targeted at mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF). Damora is based in Waltham, Massachusetts.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Galecto

Copenhagen, Denmark

Category Company
Founded 2011
Sector Life Science
Employees5
DESCRIPTION

Galecto is a clinical-stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets that are at the heart of fibrosis, inflammation, and cancer. Galecto was formed in 2011 and is based in Copenhagen, Denmark.


DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2025 M&A 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-01-07 PharmAkea

San Diego, California, United States

PharmAkea is a biopharmaceutical company and is a developer of high-quality, small molecule drug candidates against protein targets involved in fibroproliferative diseases. PharmAkea was founded in 2012 and is based in San Diego, California.

Buy -